Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria

NCT04909723 is registered in ClinicalTrials.gov with Novome Biotechnologies Inc as lead sponsor.

NCT NCT04909723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04909723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Lead sponsor
Novome Biotechnologies Inc
Phase
Phase 1/2
Overall status
Terminated
Start date
June 2, 2021
Completion date
April 6, 2023
Enrollment
153 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

enteric hyperoxaluria, healthy volunteers